Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Efinopegdutide in Metabolic Dysfunction-Associated Steatotic Liver Disease
NCT06482112Phase 2Completed
- Sponsor
- Merck & Co.
- Start
- Jul 2024
- Primary completion
- Jun 2025
- Modality
- Peptides
- Countries
- 2
01
Overview
Phase 2, randomised, open-label trial of efinopegdutide in metabolic dysfunction-associated steatotic liver disease (MASLD) (3 arms), sponsored by Merck & Co. Primary endpoints: Liver Fat Content at 28 weeks, Adverse Events at 32 weeks and 1 more. Started Jul 2024; status: completed.
02
Drugs
efinopegdutide
03
Conditions
metabolic dysfunction-associated steatotic liver disease (MASLD)
Beyond the preview
Go deeper on NCT06482112.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06482112.